| Mr Andrew E Burchard, MD | |
|
118 Dudley St, Providence, RI 02905-2403 | |
| (401) 274-2300 | |
| (401) 272-1302 |
| Full Name | Mr Andrew E Burchard |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 21 Years |
| Location | 118 Dudley St, Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730379843 | NPI | - | NPPES |
| 1730379843 | Medicaid | RI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | MD13946 (Rhode Island) | Primary |
| 207YX0905X | Otolaryngology - Otolaryngology/facial Plastic Surgery | MD13946 (Rhode Island) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Rhode Island Hospital | Providence, RI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Otolaryngology-head And Neck Surgery, Inc. | 3274613930 | 16 |
News Archive
A new research project (PneumoNP) is aimed at tackling antibiotic resistance in respiratory tract infections via the use of inhalable nanotherapeutic compounds. Funded under the FP7 programme by the European Commission, the 4-year long PneumoNP project brings together top research institutes, universities, clinicians and enterprises from 6 EU member states.
A Dutch study of the effectiveness of breast cancer screening shows that, even with improved treatments for the disease, population-based mammography programmes still save a significant number of lives.
Observing that certain cancer cells may exhibit greater flexibility than normal cells, some scientists believe that this capability promotes rapid tumor growth. Now computer simulations developed by Boston University Biomedical Engineering Assistant Professor Muhammad Zaman and collaborators at the University of Texas at Austin appear to support this view.
Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from Optimer's North American phase 3 study were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.
Echo Therapeutics, Inc., a medical device company developing its Symphony CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it entered into a strategic collaboration agreement with Medical Technologies Innovation Asia, Ltd., Hong Kong, for a license arrangement and equity investment in Echo.
› Verified 5 days ago
| Entity Name | University Otolaryngology-head And Neck Surgery, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245350958 PECOS PAC ID: 3274613930 Enrollment ID: O20080107000870 |
News Archive
A new research project (PneumoNP) is aimed at tackling antibiotic resistance in respiratory tract infections via the use of inhalable nanotherapeutic compounds. Funded under the FP7 programme by the European Commission, the 4-year long PneumoNP project brings together top research institutes, universities, clinicians and enterprises from 6 EU member states.
A Dutch study of the effectiveness of breast cancer screening shows that, even with improved treatments for the disease, population-based mammography programmes still save a significant number of lives.
Observing that certain cancer cells may exhibit greater flexibility than normal cells, some scientists believe that this capability promotes rapid tumor growth. Now computer simulations developed by Boston University Biomedical Engineering Assistant Professor Muhammad Zaman and collaborators at the University of Texas at Austin appear to support this view.
Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from Optimer's North American phase 3 study were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.
Echo Therapeutics, Inc., a medical device company developing its Symphony CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it entered into a strategic collaboration agreement with Medical Technologies Innovation Asia, Ltd., Hong Kong, for a license arrangement and equity investment in Echo.
› Verified 5 days ago
| Entity Name | The Ent Center Of Rhode Island Llc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1295906956 PECOS PAC ID: 6002974581 Enrollment ID: O20081028000419 |
News Archive
A new research project (PneumoNP) is aimed at tackling antibiotic resistance in respiratory tract infections via the use of inhalable nanotherapeutic compounds. Funded under the FP7 programme by the European Commission, the 4-year long PneumoNP project brings together top research institutes, universities, clinicians and enterprises from 6 EU member states.
A Dutch study of the effectiveness of breast cancer screening shows that, even with improved treatments for the disease, population-based mammography programmes still save a significant number of lives.
Observing that certain cancer cells may exhibit greater flexibility than normal cells, some scientists believe that this capability promotes rapid tumor growth. Now computer simulations developed by Boston University Biomedical Engineering Assistant Professor Muhammad Zaman and collaborators at the University of Texas at Austin appear to support this view.
Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from Optimer's North American phase 3 study were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.
Echo Therapeutics, Inc., a medical device company developing its Symphony CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it entered into a strategic collaboration agreement with Medical Technologies Innovation Asia, Ltd., Hong Kong, for a license arrangement and equity investment in Echo.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Andrew E Burchard, MD 118 Dudley St, Providence, RI 02905-2403 Ph: (401) 274-2300 | Mr Andrew E Burchard, MD 118 Dudley St, Providence, RI 02905-2403 Ph: (401) 274-2300 |
News Archive
A new research project (PneumoNP) is aimed at tackling antibiotic resistance in respiratory tract infections via the use of inhalable nanotherapeutic compounds. Funded under the FP7 programme by the European Commission, the 4-year long PneumoNP project brings together top research institutes, universities, clinicians and enterprises from 6 EU member states.
A Dutch study of the effectiveness of breast cancer screening shows that, even with improved treatments for the disease, population-based mammography programmes still save a significant number of lives.
Observing that certain cancer cells may exhibit greater flexibility than normal cells, some scientists believe that this capability promotes rapid tumor growth. Now computer simulations developed by Boston University Biomedical Engineering Assistant Professor Muhammad Zaman and collaborators at the University of Texas at Austin appear to support this view.
Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from Optimer's North American phase 3 study were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.
Echo Therapeutics, Inc., a medical device company developing its Symphony CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it entered into a strategic collaboration agreement with Medical Technologies Innovation Asia, Ltd., Hong Kong, for a license arrangement and equity investment in Echo.
› Verified 5 days ago
Dr. Paul C Christu, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 845 N Main St, Suit 1, Providence, RI 02904 Phone: 401-331-9690 Fax: 401-331-9609 | |
Charles M Ruhl, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 118 Dudley St, Providence, RI 02905 Phone: 401-274-2300 Fax: 401-272-1302 | |
Pamela D Dana-snyder, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 830 Chalkstone Ave, Providence, RI 02908 Phone: 401-273-7000 Fax: 401-457-1460 | |
Peter T Nigri, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 118 Dudley St, Providence, RI 02905 Phone: 401-274-2300 Fax: 401-272-1302 | |
David Samuel Bick, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 148 W River St, Suite 2a, Providence, RI 02904 Phone: 401-728-0140 Fax: 401-727-1979 | |
Jan Casimir Groblewski, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 118 Dudley St, Providence, RI 02905 Phone: 401-274-2300 | |
Dr. Frederick Augustus Godley Iii, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 845 N Main St, Suite 1, Providence, RI 02904 Phone: 401-331-9690 Fax: 401-331-9609 |